CONZIP Drug Patent Profile
✉ Email this page to a colleague
When do Conzip patents expire, and when can generic versions of Conzip launch?
Conzip is a drug marketed by Cipher Pharms Inc and is included in one NDA.
The generic ingredient in CONZIP is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Conzip
A generic version of CONZIP was approved as tramadol hydrochloride by SUN PHARM INDS INC on June 19th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CONZIP?
- What are the global sales for CONZIP?
- What is Average Wholesale Price for CONZIP?
Summary for CONZIP
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 94 |
| Clinical Trials: | 1 |
| Patent Applications: | 2,368 |
| Drug Prices: | Drug price information for CONZIP |
| What excipients (inactive ingredients) are in CONZIP? | CONZIP excipients list |
| DailyMed Link: | CONZIP at DailyMed |
Recent Clinical Trials for CONZIP
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medical College of Wisconsin | Phase 2 |
Pharmacology for CONZIP
| Drug Class | Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists |
US Patents and Regulatory Information for CONZIP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipher Pharms Inc | CONZIP | tramadol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022370-001 | May 7, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cipher Pharms Inc | CONZIP | tramadol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022370-003 | May 7, 2010 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cipher Pharms Inc | CONZIP | tramadol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022370-004 | Aug 1, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cipher Pharms Inc | CONZIP | tramadol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022370-002 | May 7, 2010 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CONZIP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cipher Pharms Inc | CONZIP | tramadol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022370-001 | May 7, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Cipher Pharms Inc | CONZIP | tramadol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022370-003 | May 7, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| Cipher Pharms Inc | CONZIP | tramadol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022370-002 | May 7, 2010 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CONZIP
See the table below for patents covering CONZIP around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2002337967 | EXTENDED RELEASE COMPOSITION CONTAINING TRAMADOL | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2004110410 | ⤷ Sign Up | |
| Canada | 2495463 | COMPOSITION A LIBERATION MODIFIEE CONTENANT DU TRAMADOL (EXTENDED RELEASE COMPOSITION CONTAINING TRAMADOL) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CONZIP
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0566709 | SPC/GB04/012 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925 |
| 0566709 | C300152 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
